REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIALJonathan Corren, David Rosmarin, P. Lio et al.|Annals of Allergy Asthma & Immunology|2025Cited by 1
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose AdalimumabAnika M. Valk, Theo Rispens, Floris C. Loeff et al.|BioDrugs|2026Cited by 0
73858 Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic DermatitisSohail Chaudhry, Jonathan Zalevsky, Jonathan Silverberg et al.|Journal of the American Academy of Dermatology|2026Cited by 0